Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach Is Likely Nominee For Permanent FDA Commissioner

This article was originally published in The Gray Sheet

Executive Summary

FDA Acting Commissioner and National Cancer Institute Director Andrew von Eschenbach will likely be nominated by President George W. Bush as the permanent head of the agency, former FDA Associate Commissioner for External Relations Peter Pitts said March 9

You may also be interested in...



NCI Director And Former Dx Start-Up Founder Sharpless Will Helm FDA

After a week of speculation as to who will succeed US FDA Commissioner Scott Gottlieb when he steps down next month, Health and Human Services Secretary Alex Azar announced during a congressional hearing that National Cancer Institute Director Ned Sharpless will step in as acting commissioner. One note of medtech interest in Sharpless' bio: he was a co-founder of a diagnostics company.

Acting Chief von Eschenbach Brings Zeal For Imaging To FDA

Andrew von Eschenbach's role in supporting the development of imaging and other diagnostic technology as director of the National Cancer Institute could inform his approach to medical device regulatory issues as he takes on the added role of acting FDA commissioner

Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

UsernamePublicRestriction

Register

MT023324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel